Abstract
Objectives: Postprandial hyperglycaemia has emerged as widely accepted cardiovascular risk factor in diabetic patients. Acceptable postprandial glycemic control is easier to achieve by intensified insulin therapie by using insulin analogues than by using normal human insulin. Patients benefit from the possibility of injecting insulin analogues after meals. There was controversy, however, whether insulin resistance in type 2 diabetic patients might hamper postprandial glycemic control by insulin analogues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Experimental and Clinical Endocrinology & Diabetes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
